替罗非班在急性进展性脑梗死中应用

Effect of tirofiban in patients with acute cerebral infarction

目的:探讨替罗非班联合阿司匹林、氯吡格雷对急性进展性脑梗死患者的临床疗效、生活质量ADL评分、神经功能缺损NIHSS评分的影响。方法:前瞻性分析90例急性进展性脑梗死患者,随机分为观察组和对照组,各45例。对照组给予服用阿司匹林、氯吡格雷治疗,观察组在经替罗非班联合治疗(24~72)h后贯续服用阿司匹林及氯吡格雷。比较2组患者治疗后临床疗效、NIHSS评分(24 h、72 h、7 d及14 d)、ADL评分及不良反应发生率。结果:观察组总有效率为88.99%,高于对照组的71.11%(P<0.05);观察组治疗后NIHSS评分低于对照组,且观察组治疗后与治疗前ADL评分差值高于对照组(P<0.05);不良反应发生率:观察组为13.85%,对照组为7.69%(P>0.05)。结论:替罗非班联合阿司匹林、氯吡格雷能有效地改善急性进展性脑梗死患者脑组织血流,提高患者生活质量,改善神经功能,安全性较好。

Objective:To study the clinical efficacy of tirofiban combined with aspirin and clopidogrel on scores of Daily Living Ability Scale(ADL)and National Institute of Health Stroke Scale(NIHSS)in patients with acute progressive cerebral infarction.Methods:90 patients with acute progressive cerebral infarction admitted to our hospital from July 2018 to July 2019 were randomly divided into observation group and control group(45 cases).The control group was treated with aspirin and clopidogrel,on top of which the observation group was given tirofiban.The clinical efficacy,ADL,NIHSS and adverse reactions between the two groups were statistically analyzed.Results:The total effective rate was 88.89%in the observation group,71.11%in the control group(P<0.05).In the observation group,the NIHSS were lower than those during the time of 24 h,72 h,7 d and 14 d,respectively(P<0.05)and meanwhile,the differentials of ADL between post treatment and prior treatment were high than those in the control group(P<0.05).The incidence of adverse reactions was 13.85%in the observation group,7.69%in the control group(P>0.05).Conclusion:Tirofiban combined with aspirin and clopidogrel has a curative effect in acute progressive cerebral infarction,improving the brain microcirculation blood flow and nerve function,enhancing life quality of patients,and ensuring the safety of the therapy.